scispace - formally typeset
Search or ask a question
Institution

Wishard Memorial Hospital

Healthcare•Indianapolis, Indiana, United States•
About: Wishard Memorial Hospital is a healthcare organization based out in Indianapolis, Indiana, United States. It is known for research contribution in the topics: Population & Pharmacokinetics. The organization has 223 authors who have published 158 publications receiving 7253 citations.


Papers
More filters
Journal Article•DOI•
Earl A. Palmer1, John T. Flynn2, Robert J. Hardy3, Dale L. Phelps4  +181 more•Institutions (24)
TL;DR: The timing of retinal vascular events correlated more closely with postconceptional age than with postnatal age, implicating the level of maturity more than postnatal environmental influences in governing the timing of these vascular events.

613 citations

Journal Article•DOI•
TL;DR: The RMRS data model, file structures and architecture, as well as recent necessary changes to these are described as the authors coordinate a collaborative effort among all major Indianapolis hospital systems, improving patient care by capturing city-wide laboratory and encounter data.

421 citations

Journal Article•DOI•
TL;DR: This study surveyed a representative clinical sample of patients who were currently receiving allopathic care for rheumatologic conditions to determine the prevalence and types of CAM used, patients' perceptions about CAM's efficacy, reasons for using CAM, potential patient communication barriers about CAM use, and correlates of CAM use and discussion of CAM with a physician.
Abstract: Patients with rheumatologic conditions frequently use complementary and alternative medicine (CAM). Severe pain and osteoarthritis predict regular use of CAM but do not predict a greater likelihood...

399 citations

Journal Article•DOI•
TL;DR: There is evidence that a wide range of alternative therapy products have the potential to interact with warfarin, and Pharmacists and other health care professionals should question all patients about use of alternative therapies and report documented interactions to FDA's MedWatch program.
Abstract: Potential and documented interactions between alternative therapy agents and warfarin are discussed. An estimated one third of adults in the United States use alternative therapies, including herbs. A major safety concern is potential interactions of alternative medicine products with prescription medications. This issue is especially important with respect to drugs with narrow therapeutic indexes, such as warfarin. Herbal products that may potentially increase the risk of bleeding or potentiate the effects of warfarin therapy include angelica root, arnica flower, anise, asafoetida, bogbean, borage seed oil, bromelain, capsicum, celery, chamomile, clove, fenugreek, feverfew, garlic, ginger ginkgo, horse chestnut, licorice root, lovage root, meadowsweet, onion, parsley, passionflower herb, poplar, quassia, red clover, rue, sweet clover, turmeric, and willow bark. Products that have been associated with documented reports of potential interactions with warfarin include coenzyme Q10, danshen, devil's claw, dong quai, ginseng, green tea, papain, and vitamin E. Interpretation of the available information on herb-warfarin interactions is difficult because nearly all of it is based on in vitro data, animal studies, or individual case reports. More study is needed to confirm and assess the clinical significance of these potential interactions. There is evidence that a wide range of alternative therapy products have the potential to interact with warfarin. Pharmacists and other health care professionals should question all patients about use of alternative therapies and report documented interactions to FDA's MedWatch program.

352 citations

Journal Article•
TL;DR: The following discussion brings together the current understandings of these interrelated phenomena to aid a more complete picture of how they may contribute both qualitatively and quantitatively to first-pass elimination.
Abstract: This is a report of a symposium held at the March 1997 meeting of the American Society for Pharmacology and Therapeutics in San Diego. Our understanding of the events that control first-pass drug elimination in humans has increased tremendously by two sequential discoveries. First, cytochrome P-450s 3A4 and 5 are expressed at high concentrations in both hepatocytes and upper intestinal enterocytes, and therefore limit the systemic availability of many drugs. Second, P-glycoprotein is expressed at the lumenal surface of the intestinal epithelium and therefore also acts to oppose the absorption of unchanged drug. The following discussion brings together our current understandings of these interrelated phenomena to aid a more complete picture of how they may contribute both qualitatively and quantitatively to first-pass elimination.

235 citations


Authors

Showing all 224 results

Network Information
Related Institutions (5)
Eli Lilly and Company
22.8K papers, 946.7K citations

75% related

Bristol-Myers Squibb
21K papers, 932.5K citations

75% related

AstraZeneca
23.4K papers, 938.2K citations

74% related

Kaiser Permanente
24.3K papers, 1.2M citations

74% related

Amgen
13.7K papers, 804.4K citations

74% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20221
20151
20141
20123
20105
20093